Medicine · 2018 · 30 citations · 14 references
MedicineInternal MedicinePathologyClinical CardiologyDiagnostic ImagingPulmonologyAortic DiseaseAortic ImagingCardiovascular DiseaseCardiovascular PathologyVascular ImagingVascular PathologyAortic Arch BranchesAortic Arch DiseaseAortic Arch InvolvementAscending Aorta ImagingCutaneous HistiocytosisErdheim-chester DiseaseSystemic HistiocytosisVascular Involvement
Erdheim-Chester disease (ECD) is a rare histiocytosis of the "L" (Langerhans) group with multisystem involvement that can affect the large and medium-sized arteries mimicking vasculitis. Aortic involvement is common but the frequency and outcome of aortic branch vessel abnormalities are less well described.Patients with ECD were retrospectively identified. Images containing information of arterial involvement within 6 months of diagnosis were considered baseline and compared to last follow-up studies. Two physicians independently reviewed the studies to evaluate for presence of abnormalities attributable to ECD. Age and sex-adjusted logistic regression models were used to examine associations between patient characteristics and vessel involvement at baseline.Among a cohort of 64 patients with ECD, 63 had baseline imaging of vascular structures. ECD involvement of at least 1 segment of the aorta was observed in 56%. Abnormalities were also observed in aortic arch branches (26%), visceral branch arteries (40%), iliofemoral arteries (31%), coronary (5%), and pulmonary (3%) arteries. Perinephric fibrosis was strongly associated with the identification of abnormalities in the thoracic aorta (OR 4.92 [1.54, 15.75]; P = .007), abdominal aorta (OR 7.57 [2.28, 25.07]; P = .001) and visceral branch arteries (OR 6.05 [1.52, 24.03]; P = .01) but not pelvic/lower extremity arteries. Complete normalization of arterial abnormalities at follow-up was only observed in 9% or less of arterial segments involved at baseline.Aortic and aortic branch vessel abnormalities are frequently observed in patients with ECD and are often asymptomatic. Partial and/or complete resolution of arterial findings is uncommon.
14
Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart et al. · JAMA Oncology · 2017 · 405 citations · Full text
Medicine, Oncology, Pharmacology +13
Julien Haroche, Fleur Cohen‐Aubart, Jean‐François Emile et al. · Journal of Clinical Oncology · 2014 · 287 citations
Medicine, Oncology, Pharmacotherapy +13
The clinical spectrum of Erdheim-Chester disease: an observational cohort study
Juvianee Estrada‐Veras, Kevin O’Brien, Louisa C. Boyd et al. · Blood Advances · 2017 · 250 citations · Full text
Laurent Arnaud, Zoulikha Malek, F. Archambaud et al. · Arthritis & Rheumatism · 2009 · 110 citations